




PHARMACEUTICAL 2021

MUSTANG BIO INC.
Rank 119 of 402





RealRate

PHARMACEUTICAL 2021

MUSTANG BIO INC. Rank 119 of 402



The relative strengths and weaknesses of MUSTANG BIO INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MUSTANG BIO INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 66% points. The greatest weakness of MUSTANG BIO INC. is the variable Research and Development, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 180%, being 133% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	99,534
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,515
Liabilities, Non-Current	1,950
Other Assets	10,366
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-3,209
Other Revenues	0
Property and Equipment	0
Research and Development	47,301
Selling, General and Administrative Expense	9,505

Output Variable	Value in 1000 USD
Assets	109,900
Liabilities	11,465
Expenses	56,806
Revenues	0
Stockholders Equity	98,435
Net Income	-60,015
Comprehensive Net Income	-60,015
Economic Capital Ratio	180%